It is important to look at healthcare as an investment, rather than a burden on the public budget: an investment in the population, their health and…
In Conversation
The talent in Saudi Arabia is absolutely world-class; they are highly educated and extremely hard-working. They have a high sense of purpose, and are very engaged.…
The biggest opportunity [in MEA] is to help accelerate the diagnosis and treatment of patients, too many of whom fall through the gaps of healthcare coverage…
Our venture capital arm has a strategic focus which means that our main interest is not the mere financial return on investment but rather helping companies…
Since the beginning of the company’s transformational journey in 2016 we have tripled our client base and today a wide range of mostly international companies –…
The ambitious mindset that the Saudi Arabia Vision 2030 sets out fits well with the mentality we are embracing at Novartis. I like to say that…
[R&D] is the gateway to successful production and competition in the marketplace. Without R&D, DEVA would not be where it is today
We want to be the prime example of an innovative, science-driven biotech from China, showcasing the best of world capability in terms of innovation, rather than…
General attitudes towards the pharmaceutical industry have shifted, with an increasing realization of the importance of local research and production and an obligation in some geographies…
The pandemic has forced every industry to rethink its operating model. For us in pharma, COVID-19 really sped up the adoption of digitalisation
Switzerland generally offers attractive conditions and a stable environment for international companies. The country offers an environment favourable to innovation, a good infrastructure, a highly skilled…
Cellestia has established itself as one of the leading companies in the discovery, research and development of innovative, first-in-class therapeutics targeting gene transcription factors for the…
